1-4 of 4
Jean-Marie Delaisse, PhD
Close
Sort by
Journal Articles

High Dose Simvastatin Has No Beneficial Effect on Markers of Bone Turn-Over in Multiple Myeloma.

Teis E. Sondergaard, MSc, Per T. Pedersen, MD, Thomas L. Andersen, MSc, Thomas Lund, MD, Patrick Garnero, PhD, Jean-Marie Delaisse, PhD, Torben Plesner, MD
Journal: Blood
Blood (2007) 110 (11): 4824.
https://doi.org/10.1182/blood.V110.11.4824.4824
Published: 2007
Journal Articles

Bortezomib Protects Osteoblasts from Glucocorticoid-Induced Damage, and Enhances Glucocorticoid-Induced Toxicity Against Osteoclasts and Myeloma Cells.

Kent Soe, PhD, Thomas L. Andersen, MSc, Katarzyna Kupisiewicz, MSc, Torben Plesner, MD, Jean-Marie Delaisse, PhD
Journal: Blood
Blood (2007) 110 (11): 3523.
https://doi.org/10.1182/blood.V110.11.3523.3523
Published: 2007
Journal Articles

Bortezomib Transiently Inhibits Osteoclast Resorptive Activity in Cell Culture Conditions Mimicking In Vivo Intermittent Treatment.

Patrice Boissy, PhD, Thomas Lund, MD, Thomas L. Andersen, MSc, Torben Plesner, MD, Jean-Marie Delaisse, PhD
Journal: Blood
Blood (2006) 108 (11): 3508.
https://doi.org/10.1182/blood.V108.11.3508.3508
Published: 2006
Journal Articles

Interactions between Myeloma Cells and Osteoclasts Are Controlled by Unique Histological Structures Involving Vascular Compartments.

Thomas L. Andersen, MSc, Katarzyna E. Skorzynska, MD, Teis E. Sondergaard, MSc, Trine Plesner, MD, Ellen Hauge, MD, Juha Risteli, MD, Torben Plesner, MD, Jean-Marie Delaisse, PhD
Journal: Blood
Blood (2005) 106 (11): 2513.
https://doi.org/10.1182/blood.V106.11.2513.2513
Published: 2005